September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma
Jun 19, 2025, 15:30

Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma

Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:

“Nivo-AVD vs BV-AVD in older pts (60+) with Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access.”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivo-AVD vs BV-AVD

More Posts Featuring Hodgkin Lymphoma on OncoDaily.